Connect Biopharma Reports Positive Phase 2 Data for Asthma Drug Rademikibart

Key Facts

1Connect Biopharma announced that Rademikibart reduced the rate of treatment failure by 66% compared to placebo in a Phase 2 study.

2The drug showed rapid and statistically significant improvement in lung function by Day 7 of treatment.

3The company plans to engage with the FDA to align on a Phase 3 program following additional data release later this month.

In a development that highlights the potential for next-generation treatments in inflammatory diseases, Connect Biopharma has released positive topline data from its Global Phase 2 study of Rademikibart. According to reports, the drug achieved a 66% reduction in the rate of treatment failure compared to a placebo in patients with acute asthma exacerbations and Type 2 inflammation. Furthermore, the study demonstrated rapid and statistically significant improvements in lung function by the seventh day of treatment.

These clinical milestones strengthen the company's positioning within the biotech sector, as the trial evaluated the drug's ability to effectively block inflammatory pathways as an add-on therapy. Following these results, the company plans to engage with the U.S. Food and Drug Administration (FDA) to align on a Phase 3 program. This move follows the expected release of additional data later this month regarding a separate study for COPD patients.

At the close on September 14, 2026, the CNTB stock price stood at $1.73, having traded between a day high of $1.82 and a low of $1.58 per market data. Investors are looking toward the release of supplemental data later this month as a primary catalyst, while broader markets await upcoming economic indicators such as the U.S. Producer Price Index.